Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome

Journal of Clinical Pathology

Volumn 58, Issue 5, 2005, Pages 509-514

  Bondi, J ^a   Husdal, A ^a   Bukholm, G ^a   Nesland, J M ^b   Bakka, A ^a   Bukholm, I R K ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN C; CYCLIN D1; CYCLIN D3; CYCLIN E; CYCLIN H; CYCLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLON ADENOCARCINOMA; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE; COLONIC NEOPLASMS; CYCLINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 18444414011     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.020347     Document Type: Article

References (40)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Murray AW, Creative blocks: cell-cycle checkpoints and feedback controls. Nature 1992;359:599-604.
3. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-4.
4. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
5. Nasmyth K. Viewpoint: putting the cell cycle in order. Science 1996;274:1643-5.
6. Leopold P, O'Farrell PH. An evolutionary conserved cyclin homolog from drasophila rescues yeast deficient in G1 cyclins. Cell 1991;66:1207-16.
7. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 1991;66:1197-206.
8. Hengartner CJ, Myer VE, Liao SM, et al. Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases. Mol Cell 1998;2:43-53.
9. Akoulitchev S, Chuikov S, Reinberg D. TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 2000;407:102-6.
10. Garrett S, Barton WA, Knights R, et al. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Mol Cell Biol 2001;21:88-99.
11. Li H, Lahti JM, Valentine M, et al. Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: deletion of the CCNC gene in human tumors. Genomics 1996;32:253-9.
12. Ueberham U, Hessel A, Arendt T. Cyclin C expression is involved in the pathogenesis of Alzheimer's disease. Neurobiol Aging 2003;24:427-35.
13. Aaltomaa S, Eskelinen M, Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate 1999;38:175-82.
14. Korenaga D, Takesue F, Yasuda M, et al. The relationship between cyclin B1 overexpression and lymph node metastasis in human colorectal cancer. Surgery 2002;131:S114-20.
15. Florenes VA, Faye RS, Maelandsmo GM, et al. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000;6:3614-20.
16. Handa K, Yamakawa M, Takeda H, et al. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999;84:225-33.
17. Palmqvist R, Stenling R, Oberg A, et al. Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer 1998;34:1575-81.
18. Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 2001;93:283-7.
19. Bukholm IR, Husdal A, Nesland JM, et al. Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time. Breast Cancer Res Treat 2003;80:199-206.
20. Li JQ, Miki H, Wu F, et al. Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol 2002;33:1006-15.
21. Kitahara K, Yasui W, Kuniyasu H, et al. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995;62:25-8.
22. Sutter T, Doi S, Carnevale KA, et al. Expression of cyclins D1 and E in human colon adenocarcinomas. J Med 1997;28:285-309.
23. Kauzman A, Li SQ, Bradley G, et al. Cyclin alterations in giant cell tumor of bone. Mod Pathol 2003;16:210-18.
24. Namazie A, Alavi S, Olopade OI, et al. Cyclin D1 amplification and p16(MTS1/CDK41) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002;112:472-81.
25. Latif Z, Watters AD, Bartlett JM, et al. Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int 2002;89:5-9.
26. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002;62:3200-6.
27. Dukes CE. The classification of cancer in the rectum. J Pathol Bacteriol 1932;35:323.
28. Rudolph P, Kuhling H, Alm P, et al. Differential prognostic impact of the cyclins E and B in premenocausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 2003;105:674-80.
29. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res 1996;6:986-94.
30. Bondi J, Bukholm G, Nesland JM, et al. Expression of non-membraneous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 2004;112:49-56.
31. Bieche I, Olivi M, Champeme MH, et al. Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 1998;78:661-6.
32. Furihata M, Ohtsuki Y, Sonobe H, et al. Cyclin A overexpression in carcinoma of the renal pelvis and ureter including dysplasia: immunohistochemical findings in relation to prognosis. Clin Cancer Res 1997;3:1399-404.
33. Collecchi P, Santoni T, Gnesi E, et al. Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. Cytometry 2000;42:254-60.
34. Yin Y, Tainsky MA, Bischoff FZ, et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-48.
35. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7.
36. Vaziri C, Saxena S, Jeon Y, et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 2003;11:997-1008.
37. Szepetowski P, Perucca-Lostanlen D, Gaudray P. Mapping genes according to their amplification status in tumor cells: contribution to the map of 11q13. Genomics 1993;16:745-50.
38. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
39. Khoo ML, Ezzat S, Freeman JL, et al. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 2002;87:1810-13.
40. Platzer P, Upender MB, Wilson K, et al. Silence of chromosomal amplifications in colon cancer. Cancer Res 2002;62:1134-8.